Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
- None.
- None.
Insights
The scheduled FDA panel review of Guardant Health's Shield™ blood test represents a significant milestone in the field of oncology, particularly in the early detection of colorectal cancer. The blood test's potential to screen average-risk adults could transform the current landscape of cancer diagnostics, as blood-based screenings are less invasive and more accessible compared to traditional methods like colonoscopies.
From a clinical perspective, the ECLIPSE study's large patient population provides a robust dataset that could demonstrate the test's efficacy. If the FDA approves the PMA, this could lead to widespread adoption in clinical settings, potentially improving early detection rates and patient outcomes.
For investors and stakeholders in Guardant Health, the FDA's review of the Shield™ blood test is a critical event that could affect the company's valuation. Approval would likely lead to an increase in the company's revenue streams and potentially provide a competitive edge in the precision oncology market. Conversely, a delay or rejection could negatively impact the stock. It's important to monitor the outcome of the FDA panel review and consider the implications for Guardant Health's financial future.
The precision oncology industry is poised for growth, with increasing demand for non-invasive diagnostic methods. Guardant Health's Shield™ blood test, if approved, could set a new standard in colorectal cancer screening. This would not only benefit Guardant Health but could also catalyze further innovation in the sector. Stakeholders should evaluate the potential market disruption and the readiness of healthcare systems to integrate such advancements.
Guardant Health submitted the final module of its PMA for Shield on March 10, 2023. The submission includes data from the company’s positive ECLIPSE study, an over 20,000-patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.
“We welcome the opportunity to engage in a discussion with key opinion leaders about our study results and the power of Shield in closing the screening gap once FDA approved,” said AmirAli Talasaz, co-CEO of Guardant Health. “The proposed timing of the meeting is in line with our expectation to complete the PMA process and launch Shield IVD in 2024.”
About Guardant Health
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements relating to Guardant Health’s future results, or regarding the potential benefits and advantages of Guardant Health’s platforms, assays and tests, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219982476/en/
Investor Contact:
investors@guardanthealth.com
Media Contact:
Matt Burns
press@guardanthealth.com
+1 518-423-5907
Source: Guardant Health, Inc.
FAQ
When is the FDA's review of Guardant Health, Inc.'s Shield blood test for colorectal cancer scheduled?
What study data is included in Guardant Health, Inc.'s PMA submission for the Shield blood test?
